Steve Scherer, Ph.D.

Professor, Department of Molecular and Human Genetics

image: Steve Scherer, Ph.D.Contact information

sscherer@bcm.edu

Publications

2023
Alge JL, Bekheirnia N, Willcockson AR, Qin X, Scherer SE, Braun MC, et al.. Variants in genes coding for collagen type IV α-chains are frequent causes of persistent, isolated hematuria during childhood. Pediatr Nephrol. 2023;38(3):687-695.

Hari A, Zhou Q, Gonzaludo N, Harting J, Scott SA, Qin X, et al.. An efficient genotyper and star-allele caller for pharmacogenomics. Genome Res. 2023;33(1):61-70.

2022
Bi W, Yuan B, Liu P, Murry JB, Qin X, Xia F, et al.. Recurring germline mosaicism in a family due to reversion of an inherited derivative chromosome 8 from an 8;21 translocation with interstitial telomeric sequences. J Med Genet. 2022;.

Wang L, Scherer SE, Bielinski SJ, Muzny DM, Jones LA, Black JLogan, et al.. Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. Genet Med. 2022;24(5):1062-1072.

Lopes JL, Harris K, Karow MBeth, Peterson SE, Kluge ML, Kotzer KE, et al.. Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing?. J Mol Diagn. 2022;24(3):253-261.

Langlois AWR, El-Boraie A, Fukunaga K, Mushiroda T, Kubo M, Lerman C, et al.. Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes. Pharmacogenet Genomics. 2022;32(4):159-172.

Gaedigk A, Boone EC, Scherer SE, Lee S-B, Numanagić I, Sahinalp C, et al.. CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project. J Mol Diagn. 2022;24(4):337-350.

2021
Henderson YC, Mohamed ASR, Maniakas A, Chen Y, Powell RT, Peng S, et al.. A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. J Clin Endocrinol Metab. 2021;106(10):2962-2978.

Maniakas A, Henderson YC, Hei H, Peng S, Chen Y, Jiang Y, et al.. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity. J Clin Endocrinol Metab. 2021;106(11):e4652-e4665.

2020
Claw KG, Beans JA, Lee S-B, Avey JP, Stapleton PA, Scherer SE, et al.. Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. Nicotine Tob Res. 2020;22(6):910-918.

Bielinski SJ, St Sauver JL, Olson JE, Larson NB, Black JL, Scherer SE, et al.. Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol). Int J Epidemiol. 2020;49(1):23-24k.

2019
Devarajan S, Moon I, Ho M-F, Larson NB, Neavin DR, Moyer AM, et al.. Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in and . Drug Metab Dispos. 2019;47(4):425-435.

Midro AT, Tommerup N, Borys J, Panasiuk B, Kosztyła-Hojna B, Zalewska R, et al.. Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies syndrome due to disruption of BPTF in a 35-year-old man initially diagnosed with Silver-Russell syndrome. Clin Genet. 2019;95(4):534-536.

Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JGoo, et al.. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019;26(8):2241-2256.e4.

2018
Sá ACaroline C, Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, et al.. Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Med Genomics. 2018;11(1):55.

Tanner J-A, Zhu AZ, Claw KG, Prasad B, Korchina V, Hu J, et al.. Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. Pharmacogenet Genomics. 2018;28(1):7-16.

Singh S, Wang Z, Shahin MH, Langaee TY, Gong Y, Turner ST, et al.. Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide. Pharmacogenet Genomics. 2018;28(11):251-255.

McDonough CW, Magvanjav O, Sá ACC, Rouby NMEl, Dave C, Deitchman AN, et al.. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018;11(4):e001854.

Numanagić I, Malikić S, Ford M, Qin X, Toji L, Radovich M, et al.. Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes. Nat Commun. 2018;9(1):828.

2017
Sá ACaroline C, Webb A, Gong Y, McDonough CW, Datta S, Langaee TY, et al.. Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. Sci Rep. 2017;7(1):16068.